Passage Bio, Inc. (NASDAQ:PASG – Get Rating) has been assigned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have updated their coverage on the […]
Aziyo Biologics (NASDAQ:AZYO – Get Rating) and Passage Bio (NASDAQ:PASG – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations. Profitability This table compares Aziyo Biologics and Passage Bio’s […]
PHILADELPHIA, April 21, 2023 Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced. | April 21, 2023
Passage Bio, Inc. (NASDAQ:PASG – Get Rating) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have covered the stock in the last year […]
Passage Bio, Inc. (NASDAQ:PASG – Get Rating) has earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued ratings on the stock in the last […]